Tag Archives: United States Senate Committee on Finance

Judgment Day for Avandia

By Oriana Schwindt | Published: July 14, 2010
Judgment Day has finally arrived for GSK’s Avandia. FDA’s Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees met July 13 and 14 to finally recommend, after months of deck-stacking against GSK, that the drug be severely restricted, if not outright pulled from the market. In the vote, 12 of 33 panelists [...]
Posted in FDA, Regulatory | Also tagged , , , , , , | Leave a comment

The Trouble with Transparency

By George Koroneos | Published: November 6, 2009
Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. She always travels first-class and has [...]
Posted in Guest Blog, Strategy | Also tagged , , , , , , | Leave a comment

Tauzin to Boehner: Don’t “Bully” Me

By Walter Armstrong | Published: August 19, 2009
Image via Wikipedia PhRMA chief Billy Tauzin so far shows no sign of waving the white flag in response to an accusatory missive from House Minority Leader Rep. John Boehner bludgeoning his former Republican colleague for leading the drug industry’s support of President Obama’s healthcare reform effort. Pointedly CC’d to pharma CEOs – Tauzin’s employers—and simultaneously [...]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment